Obtained Korean Drug Registration Certificate
April 17, 2025
Source: drugdu
98
On April 15, Tonghe Pharmaceutical announced that the company recently received the drug registration certificate for Asartan Potassium issued by the Korean Ministry of Food and Drug Safety. The manufacturer's name is Jiangxi Tonghe Pharmaceutical Co., Ltd., the manufacturer's address is Fengxin High-tech Industrial Park, Jiangxi Province, the certification scope is Asartan Potassium API, the certificate number is 2025-A1-0844, and the issuance date is 2025.04.14. Asartan Potassium is suitable for the treatment of primary hypertension in adults. The company's Asartan Potassium product has obtained the Korean Drug Registration Certificate, which means that the company's Asartan Potassium API has obtained access to the Korean market, which will play a positive role in the company's further expansion of international market business.
https://finance.eastmoney.com/a/202504153377409386.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bivalirudin for injection obtains marketing authorization from the Australian Therapeutic Goods Administration May 8, 2025
- HDM2005 for injection obtains drug clinical trial approval notice May 8, 2025
- The 10 billion-dollar ankylosing spondylitis market is undergoing a transformation May 8, 2025
- The 100 billion yuan autoimmune disease prevention market, the next outbreak point May 8, 2025
- Medical research has found that those who did not develop lung cancer despite having pneumonia all had these three dietary habits. May 8, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
